Arbutus Biopharma Files 8-K
Ticker: ABUS · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Arbutus Biopharma filed an 8-K on Oct 7, 2025. No major news, just routine filing.
AI Summary
Arbutus Biopharma Corporation filed an 8-K on October 7, 2025, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuticals Corp, is incorporated in British Columbia, Canada, and its principal executive offices are located in Warminster, Pennsylvania. The filing does not disclose specific transactions or financial figures but serves as a notification of events and accompanying exhibits.
Why It Matters
This filing indicates that Arbutus Biopharma has made a regulatory submission to the SEC, which may contain important updates or disclosures about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, without specific material financial transactions or significant operational changes detailed within the provided text.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- October 7, 2025 (date) — Date of earliest event reported
- Warminster, Pennsylvania (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Arbutus Biopharma Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 7, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 7, 2025.
What was Arbutus Biopharma Corporation's former name?
Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.
Where are Arbutus Biopharma Corporation's principal executive offices located?
Arbutus Biopharma Corporation's principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania, 18974.
What is the Commission File Number for Arbutus Biopharma Corporation?
The Commission File Number for Arbutus Biopharma Corporation is 001-34949.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-10-07 08:01:34
Filing Documents
- f8k_100625.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-25-006316.txt ( ) — 224KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_100625_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 7, 2025, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting 2025, taking place November 7–11, 2025 in Washington, DC. The AB-101 abstract has been selected as a Poster of Distinction. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated October 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: October 7, 2025 By: /s/ Tuan Nguyen Tuan Nguyen Chief Financial Officer